VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PRVAPrivia Health Group, Inc.
$25.57$3.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPRVACash Flow

Privia Health Group, Inc. (PRVA) Cash Flow Statement

8Y historyFree accessUpdated daily

Free cash flow remains highly unstable, swinging from a 23.6% margin in 2025Q4 to a negative 8.2% in 2026Q1, largely driven by lumpy working capital movements and acquisition-led capital allocation.

PRVA Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations138M163.4M109.28M80.78M47.2M55.06M38.89M24.36M5.25M
Operating CF Margin %-7.7%6.29%4.87%3.48%5.7%4.76%3.1%0.8%
Operating CF Growth %-55.17%49.53%35.28%71.17%-14.28%41.57%59.66%364.05%-
Net Income21.76M22.92M14.38M23.08M-12.06M-190.65M30.9M7.95M-4.19M
Depreciation & Amortization11.29M9.91M7.27M6.53M4.57M2.46M1.83M1.43M1.07M
Stock-Based Compensation18.85M00067.36M253.53M484K207K1.94M
Deferred Taxes11.69M10.87M8.82M7.46M-7M-28.41M-7.83M716K-258K
Other Non-Cash Items58.92M75.42M59.34M35.05M687K157K134K332K147K
Working Capital Changes14.9M44.29M19.47M8.66M-6.35M17.97M13.37M13.73M6.54M
Change in Receivables-76.89M-36.67M-19.82M-96.88M-72.2M-14.64M-21.78M-6.18M320K
Change in Inventory000000000
Change in Payables25.86M14.82M52.85M118.36M6.85M04.71M-4.14M-983K
Cash from Investing-193.04M-181.57M-10.32M-48.01M-104K-32.77M-380K-5.71M-165K
Capital Expenditures-1.23M-1.2M-5.02M-113K-104K-547K-380K-5.71M-220K
CapEx % of Revenue0.05%0.06%0.29%0.01%0.01%0.06%0.05%0.73%0.03%
Acquisitions-193.16M-181.72M-5.3M-47.89M125K-32.23M0055K
Investments---------
Other Investing1.34M1.34M00-125K0000
Cash from Financing5.23M6.7M2.68M8.74M-19.68M213.66M-767K-10.87M15.36M
Debt Issued (Net)-2.46M-2.46M00-33.25M-875K-875K-10.87M15.25M
Equity Issued (Net)6.58M8.05M2.68M8.74M13.45M223.69M000
Dividends Paid000000000
Share Repurchases000000000
Other Financing1.11M1.11M00125K-9.15M108K0106K
Net Change in Cash-49.81M-11.46M101.64M41.52M27.41M235.94M37.74M7.78M20.44M
Free Cash Flow136.77M162.2M104.26M80.67M47.09M54.51M38.51M18.65M5.03M
FCF Margin %6.09%7.64%6%4.87%3.47%5.64%4.71%2.37%0.76%
FCF Growth %15.56%55.57%29.24%71.31%-13.61%41.55%106.5%270.83%-
FCF per Share1.051.260.830.650.430.510.360.180.05
FCF Conversion (FCF/Net Income)6.28x7.13x7.60x3.50x-5.50x-0.29x1.24x2.95x-1.72x
Interest Paid0000713K888K1.93M9.2M3.72M
Taxes Paid0000307K504K381K316K27K

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Working capital volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Obscured by Volatility

As reported in recent financial statements, PRVA's operating cash flow to net income ratio has fluctuated wildly, ranging from a negative 16.14 in 2026Q1 to a positive 22.59 in 2023Q4, indicating that reported net income is a poor proxy for the company's actual cash-generating capacity.

The extreme divergence between net income and operating cash flow suggests that accounting accruals and the timing of shared savings payments significantly distort the company's reported profitability. Investors should interpret these figures with caution, as the underlying cash reality appears far more sensitive to operational timing than the smoothed net income figures imply.

Working Capital Swings Drive Liquidity

Based on quarterly filings, PRVA experiences massive swings in working capital, evidenced by an $80.9 million outflow in 2026Q1 following a $99.7 million inflow in 2025Q4, which highlights the lumpy nature of cash collections within the company's value-based care revenue model.

These dramatic shifts in working capital suggest that the company's cash position is highly dependent on the timing of CMS and payer settlements rather than consistent operational efficiency. This volatility warrants further investigation into the predictability of cash inflows, as the current pattern makes short-term liquidity forecasting exceptionally difficult for external observers.

Acquisition-Led Capital Allocation Strategy

According to historical data, PRVA has prioritized inorganic growth, with net acquisition outflows reaching $92.7 million in 2025Q4, demonstrating a clear preference for deploying capital toward expanding its provider footprint rather than returning cash to shareholders through dividends or buybacks.

The company's aggressive acquisition strategy appears to be the primary engine for its scale-up phase, though it consumes a significant portion of the cash generated during peak collection periods. Investors should monitor whether these acquisitions provide the expected accretive value, as the current capital allocation model leaves little room for error if integration efforts fail to yield anticipated synergies.

FCF Trajectory Remains Highly Unstable

As indicated by the provided cash flow data, PRVA's free cash flow margin has swung from a negative 8.2% in 2026Q1 to a positive 23.6% in 2025Q4, reflecting a lack of consistent cash flow generation despite the company's ongoing efforts to scale its physician network.

The erratic nature of free cash flow suggests that the business model is not yet generating the stable, predictable cash flows required to support a mature valuation. This instability may indicate that the company is still in a high-investment phase where cash flow is secondary to the pursuit of market share and provider density.

PRVA — Frequently Asked Questions

Quick answers to the most common questions about buying PRVA stock.

How much cash does Privia Health Group, Inc. (PRVA) generate from operations?

Privia Health Group, Inc. (PRVA) generated $163.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Privia Health Group, Inc.'s free cash flow?

Privia Health Group, Inc. (PRVA) generated $162.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Privia Health Group, Inc.'s capital expenditure (CapEx)?

Privia Health Group, Inc. (PRVA) spent $1.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.